FLASHBACK (Three Years Ago)
JAE-WON
I spotted her the moment she walked onto the stage.
The Seoul International Bio-Ethics Conference was usually a parade of gray suits and grayer ideas-academics more interested in theoretical posturing than actual innovation. I attended out of obligation, not interest. My company sponsored the event. My presence was expected.
But then she appeared.
Dr. Celeste Moreau. The name on the program meant nothing to me. Another Western researcher with another paper about moral frameworks and regulatory oversight. I'd planned to leave after the keynote.
I stayed.
She wore a simple black dress, her dark hair pulled back, and when she spoke, the entire auditorium seemed to lean forward. Not because she was loud or dramatic. Because she was precise. Confident. Every word chosen with the same care a surgeon chooses an incision point.
"We stand at a crossroads," she said, her accent turning the English words into something almost musical. "Gene therapy promises miracles. But without ethical frameworks, without restraint, we become architects of our own destruction."
I leaned back in my seat, studying her.
She presented data. Charts. Case studies of experimental treatments gone wrong. Her thesis was elegant-that innovation without ethics was just expensive chaos. That we needed guardrails before we needed breakthroughs.
It was idealistic nonsense.
And I couldn't look away.
She fielded questions with grace, never stumbling, never backing down even when a German researcher tried to corner her on implementation costs. She smiled and demolished his argument in three sentences.
When the session ended, I didn't think. I just moved.
I found her in the corridor outside the main hall, surrounded by a small crowd of admirers asking questions, requesting papers, offering collaboration. She was polite to all of them, but I could see the exhaustion creeping into her smile.
I waited.
When the crowd finally dispersed, I stepped forward. "Dr. Moreau."
She turned, and up close, I realized she was younger than I'd thought. Mid-twenties, maybe. Her eyes were striking-sharp and dark, the kind that saw through bullshit immediately.
"Yes?" She tilted her head slightly, curious but cautious.
"Jae-won Choi." I extended my hand. "CEO of Choi Pharmaceuticals."
Recognition flickered across her face, followed quickly by something that might have been suspicion. "Mr. Choi. Thank you for sponsoring the conference."
"Your theories are elegant, Dr. Moreau." I kept my voice neutral, professional. "But pointless on paper."
Her eyes narrowed. "Excuse me?"
"Ethics without application is just philosophy. Pretty words that change nothing." I paused, watching her bristle. Good. I wanted her off-balance. "Come to Choi. Let's see if your principles can survive real-world application."
She stared at me for a long moment, and I couldn't tell if she was going to slap me or laugh.
She did neither.
"You're serious." It wasn't a question.
"I don't make jokes about recruitment, Dr. Moreau. You're brilliant. You're wasted in academia. Work with me. Build something that matters."
"Build something, or build your profit margin?" The challenge in her voice was sharp as glass.
I smiled. I couldn't help it. "Both. If you're good enough."
She should have walked away. Any reasonable person would have walked away.
Instead, she said, "When do I start?"
– – –
Her first day at Choi Pharmaceuticals was a Tuesday in September.
I cleared my schedule-something I never did for new hires, no matter how promising. I told myself it was strategic. She was a significant investment. I needed to ensure proper integration.
I was lying to myself.
I met her in the lobby at eight sharp. She wore a white blouse and dark slacks, her hair down this time, falling past her shoulders. Professional. Composed. But I caught the way her fingers tapped against her briefcase. Nervous.
"Dr. Moreau." I nodded. "Welcome."
"Please, call me Celeste." She smiled, and it was genuine this time. Excited. "I'm eager to see the facilities."
I gave her the full tour. Research wings. Testing labs. The gene sequencing center that had cost more than most hospitals' annual budgets. She asked questions at every stop-intelligent questions that made my department heads scramble for answers.
When we reached Lab 7, she stopped in front of a display showing our current VX-series gene therapy trial data.
"This sequence." She pointed at the screen, frowning. "You're using adeno-associated viral vectors, but the modification here-" Her finger traced a line of genetic code. "This could trigger an immune response. Have you tested for that?"
I stepped closer, looking at what she'd spotted. "We've run preliminary toxicity screens."
"Preliminary isn't enough." She turned to me, her face serious. "If you move to human trials with this configuration, you could kill someone."
The room went quiet. My lead geneticist looked like he wanted to disappear.
I studied the sequence again. She was right. We'd missed it. Or more accurately, we'd deemed the risk acceptable in pursuit of faster results.
"What would you change?" I asked.
She grabbed a tablet from the nearest workstation and started typing, pulling up molecular models, running simulations. I watched her work-the way she bit her lower lip when she concentrated, the way her fingers flew across the screen.
"Here." She showed me the revised sequence. "If you modify the capsid protein structure at this point, you maintain efficacy while reducing immunogenicity by approximately forty percent."
I looked at the data. Ran the numbers in my head. "This would delay the trial by three months."
"This would keep your trial subjects alive." She met my eyes, unflinching. "Isn't that worth three months?"
The debate that followed was intense. Electric. We argued over molecular structures and ethical boundaries, over speed versus safety, over what qualified as acceptable risk. My entire team watched, probably wondering if I was going to fire her on her first day.
I'd never been more fascinated in my life.
"Dinner," I said abruptly, checking my watch. It was past eight. "To continue the discussion."
She hesitated. "Mr. Choi-"
"Jae-won." I grabbed my jacket. "And it's not a request, Dr. Moreau. You just cost me three months. The least you can do is explain your reasoning over decent food."
She laughed-surprised and genuine. "Fine. But I'm choosing the restaurant."
– – –
She chose a small French bistro tucked away in Itaewon, far from the glass towers of Gangnam.
We sat by the window, Seoul glittering below us like a circuit board, and talked. About science. About ethics. About the impossible balance between innovation and caution.
Somewhere between the wine and dessert, the professional line blurred.
I watched her talk, animated and alive, and realized I wasn't thinking about gene sequences anymore.
"You're staring," she said softly.
"I know."
She should have looked away. Should have made an excuse and left.
Instead, she leaned closer.
The kiss was a collision-intellect and hunger, restraint and desire, everything we'd been dancing around all day crashing together at once.
When we finally pulled apart, both breathless, she whispered, "This is a terrible idea."
"I know," I said again.
And kissed her anyway.
